Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

Background: Metastatic renal cell carcinoma (mRCC) is notably resistant to chemotherapy and radiotherapy. However, tyrosine kinase inhibitors (TKIs) and checkpoint immunotherapy have significantly improved outcomes. Still, about 20% of patients experience disease progression as their best response t...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Jakob N. Henriksen, Charlotte U. Andersen, Frede Donskov, Elke Hoffmann-Lücke, Eva Greibe, Niels Fristrup
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Medical Journals Sweden 2025-06-01
Rangatū:	Acta Oncologica
Ngā marau:	Metastatic renal cell carcinoma tyrosine kinase inhibitors therapeutic drug monitoring personalized medicine toxicity management
Urunga tuihono:	https://medicaljournalssweden.se/actaoncologica/article/view/43693
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!